Two Prior Lines News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Two Prior Lines. Real-time updates on events, politics, business and more.

FDA Grants BLA for Dato-DXd to Treat Unresectable, Metastatic HR-Positive, HER2-Negative Breast Cancer

April 2, 2024

The decision follows phase 3 trial results that demonstrated improved progression-free survival and confirmed the safety of Dato-DXd in patients with breast cancer.

Ken Takeshita Susan Galbraith Daiichi Sankyo Sebastian Kaulitzki Randomized Study Versus Investigator

Source: pharmacytimes.com

Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer

September 29, 2023

The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.

United States Ken Takeshita Daiichi Sankyo Susan Galbraith Oncology Research Eastern Cooperative Oncology Group

Source: ajmc.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Two Prior Lines News Today

FDA Grants BLA for Dato-DXd to Treat Unresectable, Metastatic HR-Positive, HER2-Negative Breast Cancer

Dato-Dxd Shows Survival Improvements in HR+/HER2&#x2013; Breast Cancer

Explore More Categories

Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer